Shots: ImaginAb to receive license fees for providing ongoing technical, clinical, and regulatory support to facilitate the successful implementation of its CD8 ImmunoPET technology Following the new agreement, ImaginAb will […]readmore
Tags : CD8 ImmunoPET technology
Shots: ImaginAb to receive license fees and payments for manufacturing and other support and will supply clinical doses of 89Zr CD8 Immuno-PET agent to Pfizer for use in select oncology […]readmore
Shots: ImaginAb signs a multi-year agreement with AstraZeneca, Pfizer & Takeda for the development of ImaginAb’s CD8 ImmunoPET technology. The global companies will get early access to clinical and imaging […]readmore